Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI89WD
|
|||
| Drug Name |
A167
|
|||
| Synonyms |
KL-A167
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Phase 3 | [1] | |
| Company |
Klus Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05294172) KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Klus Pharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.